Q4 FY26 Quarterly Investor Presentation & Webinar

Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") is pleased to provide below its Q4 FY26 Investor Presentation and Investor Webinar with CEO, Dr Luke Reid presenting.

Quarterly Investor Webinar

Presented by: CEO, Dr Luke Reid
Date & Time: 12:00pm (Midday) AEST (Brisbane/Sydney/Melbourne) on Thursday, 16 July 2026
Webinar Registration: Registration is required to attend the Quarterly Investor Webinar. Please register for the Webinar via Microba's Investor Hub at the following link: https://ir.microba.com/webinars/yOO1wy-q4-fy26-quarterly-investor-webinar

Webinar Recording: A recording will be made available at the same link following the conclusion of the live webinar.

Submit Your Questions

We invite investors and interested parties to submit questions ahead of the Quarterly Investor Webinar through the 'Ask a question' section of Microba's interactive investor platform by following this link: https://ir.microba.com/webinars/yOO1wy-q4-fy26-quarterly-investor-webinar

Stay Informed

To receive notifications when Microba releases its Quarterly Reports & Appendix 4C, Investor Presentations, and other key announcements, sign up to the Microba Investor Hub:

1. *Visit* https://ir.microba.com/welcome
2. *Follow the prompts to sign up for an account.*
3. *Complete your account profile.*

This announcement has been authorised for release by the Board of Directors

For further information, please contact:

Dr Luke Reid
Chief Executive Officer
luke.reid@microba.com
https://ir.microba.com/welcome

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit www.microba.com

microba

Q4 FY26 Results

Building the platform for personalised, microbiome-based healthcare

ASX: MAP
16 JULY 2026

Authorised for release by the Board of Directors

Disclaimer

This presentation (**Presentation**) has been prepared by Microba Life Sciences Limited (**Microba**).

Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its absolute discretion, but without being under any obligation to do so, update or supplement this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Microba or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the *Corporations Act 2001* (Cth) (**Corporations Act**).

Industry and market data – In this Presentation, Microba refers to certain market, industry, and statistical data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither Microba nor its representatives have independently verified any such data and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy. Some data is also based on the good faith estimates of Microba, which are derived its reviews of internal sources as well as the independent sources described above.

Not an offer - This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this Presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice. Any non-compliance with these restrictions may contravene applicable securities laws.

Not investment or medical advice - The information contained in this Presentation is not investment, financial product advice, medical advice or any medical recommendation or recommendation to acquire Shares. This Presentation has been prepared without taking into account your investment objectives, financial situation, medical or any other particular needs This Presentation does not and will not form any part of any contract for the acquisition of shares. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation. Before making an investment decision, you should consider whether it is a suitable investment for you in light of your own investment objectives, financial situation and particular needs and having regard to the merits or risks involved. Independent financial advice is recommended.

Future performance - This Presentation contains forward looking statements. Forward-looking statements generally relate to current expectations, hopes, beliefs, intentions, strategies or productions about future events or Microba's future financial or operating performance. For example, statements regarding anticipated growth in the industry in which Microba operates and anticipated growth in demand for Microba's products and services, projections of Microba's future financial results and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "pro forma", "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside the control of Microba. You are cautioned not to place undue reliance on any forward looking statement. Forward looking statements in this Presentation are based on assumptions and contingencies which are subject to change without notice. Actual results, performance or achievements may vary materially from any forward looking statements and the assumptions on which statements are based. The forward looking statements in this Presentation are based on information available to Microba as at the date of this Presentation and nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Except as required by law or regulation, Microba undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.

Financial data – All dollar values in Australian dollars (A$ or $) unless otherwise stated. Recipients should note that this Presentation contains historical and pro-forma financial information. Any financial information provided in this Presentation is for illustrative purposes only and is not represented as being indicative of Microba's views on its future financial condition and/or performance.

Trademarks – This Presentation may contain trademarks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, trade names and copyrights referred to in this Presentation may be listed without the © or ® symbols, but Microba asserts, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, trade names and copyright.

Disclaimer - Except for any statutory liability which cannot be excluded, Microba, its related bodies corporate and their respective officers, employees and advisers expressly disclaim all liability (including negligence) for any direct or indirect loss or damage which may be suffered by any person in relation to, and take no responsibility for, any information in this Presentation or any error or omission therefrom, and make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of this Presentation.

Section 1

Q4 FY26 Financial Highlights

Strong Q4 Core Testing Growth

+54% YoY volume.

Annualised run rate of 25,000+



Core Testing includes Microbiome Explorer and MetaPanel across Australia and the United Kingdom

Strong FY26 Core Testing Growth

+78% YoY volume.

+92% YoY revenue.



Core Testing includes Microbiome Explorer and MetaPanel across Australia and the United Kingdom

Strong FY26 Continuing product growth

+53% YoY Continuing revenue.

-72% YoY Discontinued revenue.



Continuing products includes Microbiome Explorer, MetaPanel, GI Navigator, key partners (Sonic, SYNLAB & Genova), and Invivo Supplements
Discontinued products includes Insight, legacy partners (e.g. G42), DFH distributed supplements

microba

Section 2

Q4 FY26 Business Highlights

microba

Sub-Section 2.1

Key Highlights

Growing key enterprise accounts in Australia

- In Australia, adoption has now moved beyond innovators into early adopters, increasingly characterised by enterprise-style contracts with healthcare clinics.
- Since we commenced targeting these key accounts in November 2025, we have already signed 43 accounts and sold over 5,600 tests, up 87% QoQ. These accounts represent an ordering potential of over 24,000 tests per annum.
- There are over 175 key account targets currently in the pipeline in Australia, with an estimated ordering potential of over 80,000 tests per annum.



Upcoming New Product Release

New Test Release

Targeting release in Q1 FY27

On track to launch GI Navigator, a new category-defining testing product, in September 2026. This product is the culmination of several years of leadership at the forefront of this new diagnostic category. It represents a meaningful leap in the clinical application of complete microbiome and gut testing and is expected to open up our serviceable addressable market to more medical doctors, a significant next segment of the healthcare practitioner market for our tests.

GI Navigator is live now with a closed-group early access cohort of opinion-leading practitioners across AU and UK, with the first 35 sales achieved: multiple parts of the product are already delivering clinical value and receiving positive feedback, the new product is powered by Microba’s proprietary one-of-a-kind Clinical Logic Engine.

Sub-Section 2.2

Diagnostic Results

Strong growth in Core Test sales and clinical adoption in Australia





Strong growth in Core Test Volume

- Q4 Microbiome Explorer AU test sales of 5,311, up 54% vs PCP
- Q4 Microbiome Explorer AU annualised run-rate of 21,000+ tests sold
- Q4 MetaPanel AU test sales of 225, down 15% vs PCP

Strong growth in orders per clinician

- Ordering clinicians grew 22% YoY, whilst orders per clinician grew by 34% YoY, representing the focus in Australia on signing and maturing key enterprise accounts sales

Continued progress in UK market development for Microbiome Explorer





Progress in UK market development

- Q4 Microbiome Explorer UK test sales of 825, up 92% vs PCP
- Q4 Microbiome Explorer UK annualised run-rate of 3,300 tests sold

Growing clinician accounts and orders per accounts

- Ordering clinicians grew 230% YoY, alongside orders per clinician growing by 37% YoY

Sub-Section 2.3

Supplement Results

Supplement growth focused on Invivo branded products





- Invivo Supplements revenue of $0.75m in Q4, up 11% QoQ and up 11% vs PCP
- Invivo's leading supplement PHGG's unit sales more than doubled to 43,000 units in FY26, up 114% v FY25.
- The Invivo subscription offering, launched in late 2025, grew 230% over the six months to 30 June 2026, and now has more than 1,000 subscribers.
- The Invivo supplement business continues to accelerate its transition to a focus on high margin Invivo branded products.

Sub-Section 2.4

Therapeutic Partnering

Active partnering for pipeline of therapeutic assets backed by big-data, preclinical and clinical validation

- 5+ years of investment to develop a rich pipeline of live biotherapeutic assets and data, leveraging Microba's world leading databank generated from its testing business
- Multiple microbiome therapeutics sector read outs delivered since Nov-25 validating the modality for pharma partners
- **Microba's Therapeutics division is active in a partnering process with a Boston-based advisor for its field-leading assets**
- **Recent deal precedents ranging between $1.5 – $11B**

LBP = Live Biotherapeutic Product

Therapeutic Assets

Microba maintains its competitive advantage in human data-driven discovery from the human microbiome and holds field-leading live biotherapeutic IP assets with deep preclinical and early clinical validation, including MAP-315, which is near Phase 2 ready. All further internal R&D investment remains paused, as previously guided.

Core Program		Discovery R&D	Preclinical	Phase 1	Phase 2	Development Partners
IBD *Ulcerative Colitis (UC)*	MAP 315 (LBP)				Phase 2 ready	The University of Queensland Australia; mater; The University of Newcastle Australia
	Undisclosed (LBP)					
IO Immuno-oncology	MAP 315 (LBP)			Ready to move rapidly into Phase 1b		The University of Queensland Australia; Garvan Institute of Medical Research
	Undisclosed (LBP)		Pre-clinical biology supporting lead candidate selection			
Autoimmune	Undisclosed (LBP)		Laboratory & animal model experiments confirming activity			Ginkgo Bioworks; QUT Queensland University of Technology

Sector Momentum

Multiple positive microbiome therapeutics sector read outs delivered since Nov-25 continue to validate the live biotherapeutic modality across multiple chronic diseases for pharma partners.

Siolta Therapeutics	MaaT	EnteroBiotix	microbiotica	microbiotica	SERES Therapeutics
Nov 2025	Dec 2025	Jan 2026	Feb 2026	May 2026	8 Jul 2026
Successful Phase 1b/2 readout in Allergic Disease[1]	Successful Pivotal Phase 3 in Graft-Versus-Host Disease[2]	Successful Phase 2a in Irritable Bowel Syndrome[3]	Successful Phase 1b readout in Inflammatory Bowel Disease[4]	Successful Phase 1b in Melanoma	Early positive readout for enterocolitis (irEC)

Sub-Section 2.5

Focus & Catalysts

Key areas of focus & catalysts

Break-even

- Streamlining operations to a structurally lower cost base
- Full group break-even on run-rate basis in CY2027

Diagnostics

- Australia - continued growth in test sales and clinical adoption
- United Kingdom - continued growth in test sales and clinical adoption
- New GI Navigator test release

Therapeutics

- Active in formal partnering process off the back of recent positive sector trial readouts

Corporate Snapshot	
ASX Code	MAP
Market capitalisation[1]	$28.71m
Shares on issue	700.31m
52-week low / high[1]	$0.036 / $0.105
Cash Balance (30 Jun 2026)	$7.95m

Major Shareholders	
Shareholder	Ownership %[2]
Sonic Healthcare	21.68%
Perennial	13.62%
Mercer Investments (Australia)	7.59%
Thorney Investment Group	7.17%

[1] At 15 July 2026 | [2] As per latest substantial shareholder notice lodged to the ASX

microba



Share Purchase Plan

MICROBA.COM
EXPECT BETTER

Share Purchase Plan (SPP) Details

Every new share is offered at $0.05 and includes one free attaching option – on the same terms as the institutional placement.

SPP Closing Date –Tuesday 22 July 2026

Key terms

Offer price	**$0.05 per new share**
Attaching options	**One free unlisted option per new share (1:1)**
Option exercise price	**$0.0625**
Option expiry	**Three years from the date of issue**
Maximum application	**$30,000 per eligible shareholder**
Brokerage	**None**

Illustrative application amounts

Application amount	New shares	Free attaching options
$2,500	50,000	**50,000**
$5,000	100,000	**100,000**
$10,000	200,000	**200,000**
$30,000 (maximum)	**600,000**	**600,000**

Attaching options are unlisted and exercisable at $0.0625 until three years from the date of issue. The SPP New Shares and attaching options are subject to shareholder approval at the General Meeting on 24 July 2026 and are offered under a prospectus. Share and option numbers are illustrative only, based on the $0.05 offer price and rounded.
This is a summary only and not financial product advice – refer to the SPP offer booklet and prospectus for full terms.

How to participate in the SPP

Who can participate

Shareholders registered in Australia and New Zealand on the record date, Thursday 11 June 2026.

How much you can invest

Any amount up to a maximum of $30,000, at $0.05 per new share.
No brokerage applies.

How to apply

1. Read the SPP offer booklet and prospectus sent to eligible shareholders (also available on the Microba website and ASX).
2. Pay via BPAY using the reference in your personalised offer, or apply online.
3. Ensure your application and payment are received before the offer closes.

Key dates

Event	Date
Record date	Thursday, 11 June 2026
Offer opens	Friday, 19 June 2026
Offer closes	**Wednesday, 22 July 2026**
General Meeting (shareholder approval)	Friday, 24 July 2026
SPP shares and attaching options issued	Wednesday, 29 July 2026
Trading of SPP shares commences	Thursday, 30 July 2026

The SPP New Shares and attaching options are subject to shareholder approval at the General Meeting and are offered under a prospectus. Dates are indicative and may change.
This is a summary only and not financial product advice – refer to the SPP offer booklet and prospectus for the full terms and conditions.

Timetable

Event	Date
Record Date for entitlement to participate in SPP	Thursday, 11 June 2026
Voluntary Suspension lifted and announcement to ASX of the Placement and SPP	Friday, 12 June 2026
Settlement Date of New Shares (Placement)	Wednesday, 17 June 2026
Issue of New Shares (Placement)	Thursday, 18 June 2026
Lodgement of the Prospectus - SPP (Shares and Attaching Options) and the Attaching Options for the Placement	Friday, 19 June 2026
Offers open under the Prospectus	Friday, 19 June 2026
Dispatch Notice of Meeting (NoM)	Tuesday, 23 June 2026
Offers close under the Prospectus	Wednesday, 22 July 2026
Extraordinary General Meeting (EGM) - to approve all Placement Attaching Options and the New Shares and Attaching Options under the SPP	Friday, 24 July 2026
Issue of New Shares under the SPP Offer and the issue of all Attaching Options under the Placement and SPP	Wednesday, 29 July 2026
Commencement of trading of New Shares issued under the SPP	Thursday, 30 July 2026

Any shares to be taken up by Directors under the Placement will be subject to approval at the EGM with the Shares and attaching options issued after the EGM date.

microba
expect *better*

Dr Luke Reid
Chief Executive Officer
luke.reid@microba.com

Pasquale Rombola
Chair
pasquale.rombola@microba.com

Contact

Head Office
Level 10, 324 Queen Street
Brisbane QLD Australia

Laboratory
Princess Alexandra Hospital
Woolloongabba QLD Australia